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6/j.bRespiratory virus infections, such as influenza A, cause significant morbidity in hematopoietic stem cell trans-
plantation (HSCT) recipients. The clinical characteristics and impact of infection with the novel H1N1 virus in
this patient population is not yet well defined, however. HSCTrecipients diagnosed with proven or probable
H1N1 during the 2009 pandemic were identified and charts were retrospectively reviewed with analysis of
clinical descriptions, risk factors, diagnosis, treatments, and outcomes. Twenty-seven patients from twomed-
ical centers were identified. Fever and cough were themost common presenting symptoms. The incidence of
influenza lower respiratory tract infection (LRTI) was 52% (14/27). Compared with patients with LRTI, those
with influenza upper respiratory tract infection (URTI) were more likely to have a classic influenza-like
syndrome. Compared to patients with URTI, those with LRTI were started on antiviral therapy significantly
later after symptom onset (3.0 days vs 6.58 days after onset of symptoms; P 5 .03; 95% confidence interval
[CI], 0.29-6.8). Overall influenza-related 30-day mortality was 22% (6/27), and that in patients with LRTI was
43% (6/14). Chronic steroid use ($20 mg/day of prednisone equivalent) at the time of presentation was as-
sociated with LRTI (P 5 .006) and mortality (P 5 .003) on univariate analysis. Five cases were hospital-
acquired. In this first season of the novel H1N1 pandemic, infection in HSCToften presented as an atypical
severe illness with a high incidence of LRTI and high mortality.
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Influenza A is a single-stranded RNA virus of the
orthomyxovirus family. Novel H1N1 influenza A is
a reassortment of classic swine H1N1, avian Eurasian
swine H1N1, and North American human H2N2
[1,2]. Subsequent to the onset of clinical disease in
Mexico in March 2009, novel H1N1 influenza reached
pandemic status on June 11, 2009, with more than
17,700 deaths reported worldwide as ofMarch 2010 [3].
Numerous epidemiologic studies have clinically
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Patients who are immunocompromised seem to be at
greater risk for severe influenza-associated complica-
tions, prolonged viral shedding, and emergenceof antivi-
ral drug resistance [9,10]. An early report from
hospitalized patients with novel H1N1 in California
[4], and a larger series from Canada that included 168
critically ill patients [11], described thepresenceof anun-
derlying immunosuppressive disorder in 20% of cases.
Hematopoietic stem cell transplantation (HSCT)
recipients often remain profoundly immunosuppressed
after transplantation, depending on such comorbidities
as graft-versus-host disease (GVHD) and the need for
ongoing immunosuppression [12], and are at high risk
for severe infection. Community-acquired respiratory
viruses, such as respiratory syncytial virus (RSV), para-
influenza viruses, and influenza viruses, are relatively
common causes of both upper respiratory tract infec-
tion (URTI) and lower respiratory tract infection
(LRTI) in this patient population and are associated
with significant morbidity and mortality [13,14].
Historically, the H1N1 pandemic is the first influ-
enza pandemic to hit since the introduction of HSCT
into clinical practice. Case reports of H1N1 infection
after HSCT have been published [9,15,16], as has
a single-center series from a major cancer center that
Biol Blood Marrow Transplant 17:566-573, 2011 567Novel H1N1 Influenza in HSCT Recipientsincluded 21 HSCT recipients [17]. In the present
work, we present and analyze the clinical characteris-
tics and outcomes of 27 recipients of HSCT (22 allo-
geneic HSCT and 5 autologous HSCT) with proven
or probable novel H1N1 influenza at two academic
medical centers in the United States.METHODS
Identification of Patient Population
Data reports from the Infection Control Depart-
ments at the University of California San Diego
(UCSD), Oregon Health and Science University
(OHSU), and OHSU’s Center for Hematologic Ma-
lignancies were used for case identification. In 2009,
a total of 139 HSCTs (79 autologous and 60 alloge-
neic) were performed atUCSD, and 122 (66 allogeneic
and 56 autologous) were performed at OHSU. Each
patient included was at least 18 years old, had been di-
agnosed with influenza, and had undergone allogeneic
or autologous HSCT.
Novel H1N1 Influenza Identification
Four standard techniqueswereused to identify influ-
enza: influenza-specific reverse-transcriptasepolymerase
chain reaction (RT-PCR; ViraCor Laboratories, Lee’s
Summit, MO; RT-PCR provided by the Centers for
Disease Control and Prevention [CDC] and performed
by state Health Departments) or respiratory virus PCR
multiplex panel (Luminex, Austin, TX), direct fluores-
cent antibody (DFA) testing (Diagnostic Hybrids,
Diagnostics Hybrids, Athens, OH), rapid influenza
testing (BinaxNOW, Binax NOW, Inverness Medical
Professional Diagnostics, Princeton, NJ), and viral cul-
ture. Samples were collected from nasal wash, nasopha-
ryngeal swab, and/or bronchoalveolar lavage.
Case Definitions
Proven cases were defined as having confirmed
novel H1N1 influenza by PCR. Probable cases were
defined as patients who had a positive test for influenza
A in the context ofwidespread communityH1N1activ-
ity without PCR confirmation. The case definition of
classic influenza-like illness (ILI) included fever
$100.4F and at least two of the following symptoms:
cough, myalgia, sore throat, and headache. Patients
who did not meet the criteria for classic ILI were
considered to have an atypical presentation. URTI
was defined as a proven or probable case of influenza
with a clear chest radiograph and/or normal findings
on chest auscultation. LRTI was defined as hypoxia
and/or abnormal findings on chest auscultation with
new radiographic findings. Hospital-acquired infec-
tionwas defined as symptomonset$7days after admis-
sion. Influenza-related mortality was defined as deathresulting from a clinically compatible illness confirmed
to be influenza by diagnostic testing, with no period of
complete recovery between onset of illness and death.
Data Collection
Medical records of patients meeting the foregoing
inclusion criteria were retrospectively reviewed for
underlying illnesses, immunosuppressive medication
regimens, presenting symptoms, physical examination
findings, results of pertinent radiographic studies and
laboratory tests, coinfections, treatments, and out-
comes. Institutional Review Board approval was ob-
tained at both centers.
Statistical Analysis
Categorical variables were described as count and
relative frequency (%). Continuous variables were
summarized as averages, medians, and ranges. Cate-
gorical variables were compared using Fisher’s exact
test, and continuous variables were compared using
the Student t test. All P values were two-tailed, and sta-
tistical significance was set at P\ .05.RESULTS
Baseline Characteristics
Twenty-seven HSCT recipients with proven or
probableH1N1influenzaAwere identifiedat the subject
institutions between May 4, 2009, and December 18,
2009.Twenty patientsweremale (74%), and the average
patient age was 46 years (range, 20-67 years) (Table 1).
Twenty-two patients had received an allogeneic
HSCT (11 matched unrelated and 11 matched related),
and 5 had received an autologousHSCT. Seven patients
were receiving chemotherapy for relapsed disease at the
time of influenza diagnosis. The median time posttrans-
plantationwas379days (range, 5-2895days). Sixpatients
(22%) were diagnosed before day 100 posttransplanta-
tion, and 14 patients (52%) were diagnosed at 1 year or
longer posttransplantation. Eighteen patients had stable
trilineage engraftment, 4 were transfusion-dependent,
and 5 were early posttransplantation and had not yet en-
grafted. Fourteen patients were lymphopenic (absolute
lymphocyte count\500 cells/mm3) at the time of influ-
enza diagnosis. Seventeen patients (63%) had GVHD
(1 acute and 16 chronic), and 12 patients (44%) were
receiving systemic prednisone equivalent at a dose of
$20mg/day.Three patientshad received the inactivated
H1N1 influenza vaccine before diagnosis, at 0, 14, and
17 days before the onset of symptoms and 205, 468,
and 2968 days posttransplantation, respectively.
Clinical Presentation
Five patients were managed as outpatients, and 22
were managed as inpatients. Five of the inpatient cases
Table 1. Baseline Demographic Data and Transplant Status
Age, years, average (range) 46 (20-67)
Male sex, n (%) 20 (74%)
Disease, n
Non-Hodgkin lymphoma 7
Acute myelogenous leukemia 5
Acute lymphoblastic leukemia 4
Multiple myeloma 4
Chronic myelogenous leukemia 3
Hodgkin disease 2
Chronic lymphoblastic leukemia 1
Myelofibrosis 1
GVHD, n (%) 17 (63%)
Corticosteroids $20 mg/day
(prednisone equivalent), n (%)
12 (44%)
Transplant type, n (%)
Allogeneic
Matched unrelated donor 12 (44%)
Related 10 (37%)
Autologous 5 (19%)
Engraftment, n (%)
Stable engraftment 18 (67%)
Transfusion dependent 4 (15%)
Pre-engraftment 5 (19%)
Time posttransplantation, median (range) 379 days (5-2895 days)
<100 days, n (%) 6 (22%)
$365 days, n (%) 14 (52%)
Lymphopenia at diagnosis (<500 cells/mm3), n (%) 14 (52%)
GVHD indicates graft-versus-host disease.
Table 2. Signs and Symptoms
Symptom/Sign
Number of
Patients (n 5 27) %
Cough 26 96
Fever 25 93
Dyspnea 16 59
Myalgias 14 52
Nasal congestion 12 44
Chills 11 41
Sore throat 10 37
Generalized weakness 9 33
GI symptoms* 7 26
Headache 6 22
Chest pain 3 11
CNS symptoms† 2 7
*Gastrointestinal symptoms: nausea, vomiting, diarrhea.
†Central nervous system symptoms: confusion, dizziness.
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9 of admission; the other 4 developed symptoms .14
days after admission), and 17 cases presented from
the community with a primary respiratory illness and
were ultimately diagnosed with influenza. Of the 17
patients admitted for ILI, reasons for admission in-
cluded dyspnea and hypoxia in 10, fever in 1, hypoten-
sion in 1, and observation in 5.
The most common clinical symptoms at presenta-
tion were cough, fever (temperature $100.4F), and
dyspnea (Table 2). Fever ranged from 100.4F to
103F. Gastrointestinal symptoms (nausea, diarrhea)
were present in 7 patients (26%), 4 of whom had a cur-
rent or previous history of GVHD of the gastrointes-
tinal system. Central nervous system symptoms were
reported in 2 patients, one with dizziness and the other
with altered mental status. Only 16 patients (59%) had
classic symptoms as defined by the case criteria for ILI.
Fourteen patients were diagnosed with LRTI (13/22
[59%] of allogeneic HSCT recipients and 1/5 [20%]
of autologous HSCT recipients; P5 .16); the remain-
ing 13 had URTI. The incidence of LRTI was 67% in
those at \100 days posttransplantation and 48% in
those at $100 days posttransplantation (P 5 .60).Table 3. Diagnostic Testing
Diagnostic Method Patients Tested, n Tests Pe
PCR 17
Culture 17
DFA 8
Rapid test* 9
DFA indicates direct fluorescent antibody.
*Rapid test: BinaxNow, an in vitro immunochromatographic assay for qualitatSeventy-seven percent of the patients with URTI
(10/13) met the case criteria for classic ILI, compared
with only 43% (6/14) of those with LRTI.
Radiographic Studies
Chest imaging was performed in 25 patients.
Eleven patients had a normal chest radiograph at
time of diagnosis, and 14 had evidence of LRTI.
Eleven patients had diffuse bilateral infiltrates, and 3
exhibited lobar consolidation.
Virologic Diagnosis
Influenza A was documented in all 27 patients stud-
ied. PCR testing to confirmnovelH1N1was performed
in 17 cases (63%), all of which were positive (Table 3).
Probable H1N1 was diagnosed by a combination of
rapid test, DFA, and/or culture in the remaining pa-
tients. DFA was performed at only one of the institu-
tions. Of the 8 DFAs performed, 7 were positive (4
frombronchoalveolar lavage [BAL] and3 fromnasopha-
ryngeal swabs); one of these 7 was confirmed to be novel
H1N1 by PCR. Patients with URTI were diagnosed
significantly earlier than those with LRTI (mean, 2.69
days vs 5.62 days after symptom onset; P 5 .02; 95%
CI, 0.3-5.5). The 3 patients who received vaccination
before disease onset had PCR-documented novel
H1N1 influenza.
Treatment
Twenty-five patients (93%) received antiviral
treatment during the course of their illness. Nineteenrformed, n Positive Results, n % Positive
17 17 100
21 16 76
8 7 88
10 4 40
ive detection of influenza A and B nucleoprotein antigens.
Table 4. Cases, Treatment, and Outcome
Case
Sex and
Age, Years
Underlying
Disease/Transplant
Type GVHD
Lymphocyte
Count at Diagnosis,
Cells/mm3
Prednisone
$ 20 mg/Day
before Diagnosis
Days after
HSCT
Days of Symptoms
before Diagnosis
Syndrome
Related
to Influenza
Days from
Symptom Onset
to Antiviral
Treatment
Antiviral
(Treatment Days)
30-Day Outcome
(Day After
Influenza Diagnosis)
1 M, 36 AML/MUD Chronic 216 Yes 355 3 LRTI‡ 2 O/R (9) Expired (9)
2 M, 57 NHL/auto No <500 No 11 10 URTI 10 O/R (5) Recovered
3 F, 36 HD/related Chronic 600 No 912 2 URTI No treatment None Recovered
4 M, 39 ALL/MUD Chronic 396 Yes 355 1 URTI 1 O/R (5) Recovered
5 M, 61 MM/related Chronic 192 Yes 1095 9 LRTI‡ No treatment None Expired (5)
6 M, 57 CLL/MUD Chronic 600 Yes 730 1 URTI 1 O (5) Recovered
7 M, 46 NHL/auto No 1155 No 2190 3 URTI 3 O (5) Recovered
8 M, 65 NHL/MUD Acute 1024 Yes 50 * LRTI‡ * O (7) Recovered†
9 M, 51 AML/related Chronic 256 No 176 3 LRTI 3 O (8) Recovered
10 M, 55 AML/auto No <500 No 5 9 LRTI 9 O (12) Recovered
11 F, 45 MF/related Chronic 580 Yes 2555 3 LRTI‡ 3 O/R/P (7) Expired (5)
12 M, 20 ALL/related No 485 No 41 5 URTI 5 O (5) Recovered
13 F, 27 CML/related Chronic 175 No 379 9 LRTI 14 O (7) Recovered†
14 F, 36 MM/MUD Chronic 588 No 427 2 LRTI 4 O (10) Recovered
15 M, 39 ALL/MUD No 364 Yes 31 8 LRTI 11 O (11) Recovered
16 F, 57 NHL/related Chronic 1500 No 199 1 URTI 5 O (5) Recovered
17 F, 34 CML/MUD No <500 Yes 12 11 LRTI‡ 12 O/Z (4) Expired (5)
18 M, 30 HD/MUD Chronic 200 Yes 112 4 LRTI 6 O (10) Recovered
19 M, 55 MM/auto No 700 No 1395 2 URTI 2 O (5) Recovered
20 M, 46 ALL/MUD Chronic 1200 No 820 2 URTI 2 O (10) Recovered
21 M, 49 CML/related No 500 No 2007 2 URTI 1 O (5) Recovered
22 M, 67 AML/MUD Chronic 500 Yes 313 1 LRTI 3 O/P (14) Recovered†
23 M, 50 NHL/related Chronic 240 Yes 823 1 LRTI‡ 1 O (5) Expired (11)
24 M, 55 NHL/related Chronic 400 Yes 2895 10 LRTI‡ 11 O (10) Expired (12)
25 F, 21 AML/MUD Chronic 300 No 482 1 URTI 1 O (10) Recovered
26 M, 55 MM/auto No 1300 No 206 1 URTI 2 O (5) Recovered
27 M, 62 NHL/MUD No 600 No 767 4 URTI 4 O (5) Recovered
AML indicates acutemyelogenous leukemia; DLBCL, diffuse large B cell lymphoma; ALL, acute lymphoblastic leukemia; MM,multiple myeloma; CLL, chronic lymphocytic leukemia; NHL, non-Hodgkin lymphoma; CML,
chronic myelogenous leukemia; HD, Hodgkin disease; MF, myelofibrosis; LRTI, lower respiratory tract infection; URTI, upper respiratory tract infection; MUD, matched unrelated donor; O, oseltamivir; Z, zanamivir;
P, peramivir.
*Unknown.
‡Required mechanical ventilation.
†Expired after 30 days: day 64 in patient 8, day 120 in patient 13, and day 63 in patient 22.
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570 Biol Blood Marrow Transplant 17:566-573, 2011L. Espinosa-Aguilar et al.received oseltamivir monotherapy, 3 received a combi-
nation of osteltamivir and rimantidine, and 3 received
sequential therapy, 2 of whom received peramavir
(Table 4). The initial dose of oseltamivir was 75 mg
twice daily in all patients except 1, who received an ini-
tial dose of 150 mg twice daily. The starting dose of 75
mg was increased to 150 mg twice daily in 5 patients.
Treatment was initiated at a median of 3 days (range,
1-14 days) after onset of symptoms. Empiric antiviral
treatment was initiated at the time of clinical diagnosis
in 13 patients. Therapy was not initiated until virologic
diagnosis in 12 patients, including all 5 hospital-
acquired cases. Two patients did not receive treatment
for influenza; one of these patients was diagnosed post-
mortem, and the other did not fill the prescription.
Twenty-four patients receiving antiviral therapy had
a clearly defined time of symptom onset. Patients
with URTI were started on antiviral therapy earlier
than those with LRTI (mean, 3.0 days vs 6.58 days
after onset of symptoms; P 5 .03; 95% CI, 0.29-6.8).
Half of the patients with LRTI (7/14) requiredme-
chanical ventilation, 35% (5/14) required noninvasive
supplemental oxygen, and 14% (2/14) did not need
supplemental oxygen. Twenty patients (74%) received
empiric, broad-spectrum antibiotic therapy. Baseline
steroid dose was increased after influenza diagnosis
in 12 patients (44%), for indications that included
adult respiratory distress syndrome (ARDS) and cryp-
togenic organizing pneumonia.Outcomes
All-causemortality was 33% (9/27) at amedian of 83
days (range, 5-196 days) after diagnosis of influenza.
Overall influenza-related mortality was 22% (6/27) at
a median of 8 days (range, 5-12 days). All patients with
URTI (13/27) survivedwithout long-termcomplications
attributable to influenza. No patients in this series pro-
gressed fromURTI toLRTIafter diagnosis ofH1N1 in-
fluenza. The incidence of influenza pneumonia (LRTI)
was 52%(14/27),with amortality of 43%(6/14).Rapidly
progressive respiratory failure with ARDS developed in
7 patients (26%), all of whom required mechanical
ventilation; only one of these patients survived to be
extubated and discharged, but this patient died at day
64 of liver failure and sepsis. All deaths occurred in the
LRTI group, and only one patient survived intubation,
for a short period.
Three patients died .30 days after influenza was
diagnosed. In addition to the patient described earlier,
one patient suffered a fatal pulmonary embolus after
undergoing colectomy for severe Clostridium difficile
colitis, and the other had bronchiolitis obliterans.
These patients died at 63 and 120 days after diagnosis,
respectively. Other possible influenza-related compli-
cations included one case of myopericarditis and onedeath resulting from massive myocardial infarction in
the context of known severe coronary artery disease.
Diagnostic BAL (for bacterial and viral studies)
was performed in 8 of the 14 patients with LRTI.Non-
quantitative bacterial cultures were positive in 2 of
these patients, although in both cases the treating phy-
sician considered this to represent colonization rather
than actual infection. One of these patients (patient 5)
demonstrated pleural effusion (known to be malignant
effusion) on chest radiograph and growth of oral flora
and Escherichia coli in BAL fluid. The second patient
(patient 10) had hospital-acquired H1N1 and a remote
history of treatment for methicillin-resistant Staphylo-
coccus aureus (MRSA) bacteremia. MRSA grew from
BAL cultures, and the patient received vancomycin
leading up to and after bronchoscopy, although the
treating physician suspected that this represented col-
onization. There were no other suspected or docu-
mented bacterial superinfections. One patient
(patient 10) was found to be coinfected with adenovi-
rus at the time of influenza diagnosis.
Another patient (patient 22) had documented osel-
tamivir resistance with mutation H275Y (CDC and
ViraCor Laboratories). This patient received an initial
5-day course of oseltamivir, then a 15-day hiatus in
antiviral treatment, followed by a 3-day course of
oseltamivir, and finally a 6-day course of intravenous
peramivir. Active viral shedding was documented for
28 days. This was the only patient tested for antiviral
resistance based on clinical suspicion.
A steroid dose of$20mg/day of prednisone equiv-
alent at the time of influenza diagnosis was signifi-
cantly associated with the development of LRTI (71%
vs 15%; P 5 .006) and with 30-day mortality (50% vs
0%; P 5 .003). A trend toward an association of
lymphopenia with LRTI was seen (71% vs 31%; P 5
.057) (Table 5).DISCUSSION
Previous reports have provided insight into the clin-
ical features and sequelae of seasonal influenza inHSCT
recipients [18,19]. To date, there have been only limited
reports of H1N1 influenza in the same population,
however. Here, we report a series of 27 HSCT
patients with H1N1 influenza at two institutions.
Themost commonsymptomswere fever and cough,
consistent with findings from a previous series of novel
H1N1 influenza in HSCT recipients and indistinct
from the clinical picture of other respiratory viral infec-
tions [20]. The atypical presentation in patients with
LRTI was quite notable in our series. The absence of
classic presenting symptomshas beenwell characterized
withother respiratory viral infections inHSCTpatients,
in whom pneumonia may develop with mild or absent
URTI-type symptoms [14,21]. The impaired systemic
inflammatory response and immune dysregulation
Table 5. Features of URTI and LRTI
URTI
(N 513),
n (%)
LRTI
(N 5 14),
n (%) P value
Classic ILI symptoms 10 (77%) 6 (43%) .12
Lymphopenia (<500 cells/mm3) 4 (31%) 10 (71%) .057
Steroid dose $20 mg/day (prednisone
equivalent) at diagnosis
2 (15%) 10 (71%) .006
GVHD 6 (54%) 11 (78%) .30
Unrelated donor 4 (36%) 7 (50%) .60
Mortality (<30 days) 0 (0%) 6 (43%) .01
URTI indicates upper respiratory tract infection; LRTI, lower respiratory
tract infection; ILI, influenza-like illness; GVHD, graft-versus-host disease.
Biol Blood Marrow Transplant 17:566-573, 2011 571Novel H1N1 Influenza in HSCT Recipientsobserved in immunosuppressedHSCTrecipientsmight
contribute to these atypical presentations.
The most common serious complication in our
series was influenza pneumonia, occurring in more
thanhalf of thepatients.This is higher than the incidence
of LRTI reported with seasonal influenza in HSCT
recipients (5%-44%) [13,18,19,22,23] and with that
of novel H1N1 influenza in hospitalized patients
(40%-44%) [8,24]. Half of the patients with LRTI
progressed to ARDS relatively rapidly after the initial
clinical presentation. This incidence is also higher than
the incidence of ARDS in reports of novel H1N1
influenza in other populations, which has ranged from
0 to 24% [8,24,25]. The lack of clearly documented
bacterial superinfections may well result from the early
empiric use of broad-spectrum antibiotics in this patient
population.
Chronic corticosteroids and lymphopenia have been
identified as risk factors for the progression from URTI
to LRTI in HSCT recipients with respiratory virus
infection [14,26]. In our series, the use of $20 mg/day
of prednisone equivalent at time of diagnosis was
associated with LRTI and mortality. These findings are
limited by the reliance on univariate analysis, which
does not allow for independent assessment of steroid
use and LRTI as risk factors for mortality. In addition,
there was a trend toward more lymphopenia in the
LRTI group and in those with\30-day mortality, but
these associations failed to reach statistical significance.
Given the small number of patients in this series, these
findingswill need tobeconfirmed in larger future studies.
Two patients with confirmed novel H1N1 influ-
enza received the inactivated vaccine roughly 2 weeks
before symptom onset and more than 1 year after
HSCT. In healthy U.S. adults and elderly persons,
a single dose of vaccine for novel H1N1 was found
to be highly immunogenic when evaluated at 3 weeks
postvaccination [27,28]. However, the immunologic
response to influenza vaccination is suboptimal in
HSCT recipients, particularly those who recently
underwent transplantation and those on high-dose im-
munosuppressive therapy [29,30].
Early initiation of antiviral therapy in patients with
H1N1 influenza infection may attenuate the severityof disease [8,31,32]. In our series, those with LRTI
were started on antiviral therapy significantly later
after symptom onset compared with the URTI
group. This discrepancy may be related to a failure
to recognize atypical presentations of influenza
illness, contributing to delayed diagnosis in HSCT
recipients with LRTIs. We also recognize the
increasing institutional awareness of H1N1 influenza
infections over time. Thus, patients might have been
more aggressively screened and treated with antiviral
therapy later in the course of the pandemic, thereby
decreasing the delays in starting therapy and possibly
avoiding the development of LRTI.
Apart from LRTI, other complications noted in
this series included a case of myopericarditis and an
autopsy-confirmed case of bronchiolitis obliterans.
Respiratory virus infections in allogeneic HSCT
and lung transplant recipients have been demon-
strated to trigger alloimmune lung syndromes, such
as bronchiolitis obliterans and idiopathic pneumonia
syndrome, and are associated with increased mortality
[33,34].
The 30-day mortality in our series (22% overall,
and 43% in the subset with LRTI) was higher than
that reported with seasonal influenza A in HSCT re-
cipients, (0-15% and 0-28%, respectively) [13,14,18,
19,22,23], and was significantly higher than that
reported with novel H1N1 in hospitalized patients at
large (0-7%) [8,24,35]. Redelman-Sidi et al. [17]
reported no influenza-related mortality in a group of
21HSCT recipients withH1N1 infection at their cen-
ter. The striking disparity in mortality between that
series and ours is likely related to a number of factors.
Our series included more patients with LRTI (52% vs
40%), GVHD (63% vs 19%), and early (\5 months)
posttransplantation status (22% vs 0%). The higher
rates of LRTI and death in our series compared with
both seasonal and novel H1N1 reports in HSCT
might be a result of selection bias, if H1N1 was
more frequently considered and tested for in the sicker
patients. Therefore, the incidence of severe influenza
is likely overestimated in this study.
Nosocomial outbreaks of seasonal influenza have
been well described [36-38]. Nineteen percent of our
patients had hospital-acquired influenza. Antiviral treat-
ment in this group was uniformly initiated at the time
of microbiologic diagnosis rather than at the onset of
clinical symptoms. At one of the centers, no further
nosocomial cases were documented after implementa-
tion of unit-wide contact/droplet isolation and visitor
restriction policies, along with a low threshold for influ-
enza testing. Vaccination of health care workers is
another effectiveway to reducenosocomial transmission
of influenza. Although the estimated rate of seasonal
influenza vaccination rates in health care workers is
only 40% [39], mandatory vaccination has been found
to increase vaccination rates [40].
572 Biol Blood Marrow Transplant 17:566-573, 2011L. Espinosa-Aguilar et al.The present study has several limitations, includ-
ing its retrospective design and small sample size. In
addition, our series likely does not include all HSCT
patients with influenza, given that patients were cap-
tured on the basis of clinical symptoms rather than
on universal screening. Thus, patients with very mild
signs and/or symptoms of infection might not have
been identified. Only 63% of the cases were confirmed
as novel H1N1 influenza by PCR. Probable cases were
included because H1N1 was overwhelmingly the most
prevalent influenza virus in the community during the
study period [41].
In conclusion, we have reported a series of 27
HSCT recipients with novel H1N1 influenza with
a high incidence of atypical presentation and severe
disease. Patients with LRTI frequently required me-
chanical ventilation and had a high mortality rate.
Our centers’ experiences underscore the importance
of considering influenza infection in HSCT recipients
despite an often atypical presentation. Further studies
are needed to confirm these findings and delineate
other risk factors, clinical characteristics, treatment,
and mortality of novel H1N1 influenza in this patient
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